High incidence of cardiovascular events in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 68, Issue 9, 2009, Pages 1509-1510

  Steen, K S S ^a   Lems, W F ^a,b   Visman, I M ^b   Heierman, M ^b   Dijkmans, B A C ^a,b   Twisk, J W R ^a   Boers, M ^a   Nurmohamed, M T ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JAN VAN BREEMEN INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ARTERY DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; FAMILY HISTORY; FEMALE; HIGH RISK POPULATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 69949139715     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.105023     Document Type: Letter

References (10)

1. Boers M, Dijkmans B, Gabriel S, Maradit-Kremers H, O'Dell J, Pincus T. Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular co morbidity. Arthritis Rheum 2004;50:1734-1739 (Pubitemid 38725084)
2. Del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-2745 (Pubitemid 34016192)
3. Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006;5:331-337 (Pubitemid 44202201)
4. Solomon DH, Avorn J, Sturmer T, Glynn RJ, Mogun H, Schneeweiss S. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006;54:1378-1389
5. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al, MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771-1781
6. Van Doornum S, Jennings GL, Wicks IP. Reducing the cardiovascular disease burden in rheumatoid arthritis. Med J Aust 2006;184:287-290
7. Koek HL, Van Dis SJ, Peters RJG, Bots ML. Hoofdstuk 1. Hart- en vaatziekten. In Nederland in Van Leest LATM, Koek HL, Van Trijp MJCA, et al., eds. Hart- en vaatziekten in Nederland 2005, cijfers over incidentie en prevalentie. Den Haag, The Netherlands: Nederlandse Hartstichting, 2005: 23.
8. Van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Diseasemodifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006;8:R151.
9. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-1177 (Pubitemid 34304256)
10. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113:1578-1587 (Pubitemid 43739417)